Global Cardiovascular Drug Market Research and Forecast 2018-2023

Cardiovascular disease (CVD) involves heart and blood vessel blockage which leads to heart attack, chest pain and other heart problems. It is one of the leading cause of death worldwide. CVD mainly caused due to high blood pressure, smoking, diabetes, lack of exercise, obesity, high blood cholesterol, poor diet, and excessive alcohol consumption. Factors motivating the growth of cardiovascular drug market includes increasing geriatric population and changing lifestyle such as shift in work hours. Advancement in cardiovascular diagnosis procedure and technological improvement in the healthcare have fuelled the growth of this market. Growing healthcare expenditure in emerging economies and cost-effective and affordable cardiovascular solution by leading manufacturers have provided new opportunity to this market.

Geographically, Cardiovascular drug market is divided into North America, Europe, Asia Pacific and Rest of the World. In terms of revenue generation North America region represents the largest market for cardiovascular drugs. Adoption of genetic engineering in U.S for diagnosis of cardiovascular diseases is another driving factor. Increasing government funding to improve healthcare infrastructure, and rising awareness about cardiovascular drug are the major factor which drives this market in APAC region.

Browse full report at: Global Cardiovascular Drug Market

The global players in the cardiovascular drug market include Abbott laboratories, Bristol-Myers Squibb company, Sanofi, Boston scientific, C.R bard. The strategy adopted in these companies are continuous investments in (R&D) which made them progress over the past several years in offering better drug with minimum side effects. As a result, market player may offer low-cost, high-value solutions and services to various community hospitals and clinics. In January 2018, Sanofi acquired Ablynx to expand their product portfolio for rare blood disorders and continue to advance the strategic transformation for drug discovery.

The market study of Global Cardiovascular drug market is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report country level analysis is provided by analysing various regional players, regional tax laws and policies, consumer behaviour and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.

For related reports please visit: Pharmaceuticals Industry Research

Orion Market Research (OMR) a research company known for its crisp and concise reports. The company is equipped with an experienced team and young brigade of analysts.